Iradimed (IRMD) Cash from Financing Activities (2013 - 2026)

Iradimed (IRMD) has 14 years of Cash from Financing Activities data on file, last reported at -$2.6 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 14.4% year-over-year to -$2.6 million in Q1 2026; TTM through Mar 2026 was -$17.9 million, a 109.11% decrease from a year earlier, with the FY2025 full-year figure at -$17.6 million, down 22.77% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$2.6 million, up from -$10.9 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for IRMD reached as high as $52341.0 in Q3 2022 and fell as low as -$13.3 million in Q1 2023.
• Historically, Cash from Financing Activities has averaged -$3.6 million across 5 years, with a median of -$2.2 million in 2025.
• Across the five-year window, Cash from Financing Activities tumbled 34536.13% in 2022 and surged 71.67% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at -$198457.0 in 2022, then plunged by 32.32% to -$262590.0 in 2023, then plunged by 820.64% to -$2.4 million in 2024, then slumped by 349.78% to -$10.9 million in 2025, then jumped by 76.03% to -$2.6 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$2.6 million in Q1 2026, -$10.9 million in Q4 2025, and -$2.2 million in Q3 2025.